GSK
2 years ago ⋅ English ⋅ 4 min read
Newsroom
Japan’s Ministry of Health, Labour and Welfare approves GSK’s Arexvy, the country’s first respiratory syncytial virus (RSV) vaccine for older adults

For media and investors only- Arexvy’s approval will help protect adults 60 years of age and older in Japan from RSV disease for the first time, including those living with underl... Read More
GSK
2 years ago ⋅ English ⋅ 6 min read
Newsroom
European Commission authorises ViiV Healthcare’s Apretude (cabotegravir long-acting and tablets) for HIV prevention

For media and investors only- Given as few as six times per year, cabotegravir has demonstrated superior efficacy to a daily oral PrEP option (FTC/TDF tablets) in reducing the risk of H... Read More
GSK
2 years ago ⋅ English ⋅ 6 min read
Newsroom
Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anaemia

For media and investors only- Approval is for use in myelofibrosis patients with anaemia regardless of prior myelofibrosis therapy- Nearly all myelofibrosis patients are estimated to de... Read More
GSK
2 years ago ⋅ English ⋅ 4 min read
Newsroom
GSK and Save the Children renew award-winning partnership, with focus on ‘zero dose’ children who have never received a vaccine

For media and investors only- GSK and Save the Children renew their 10-year partnership for a further five years- Building on learnings over the last decade, the two organisations will... Read More
GSK
2 years ago ⋅ English ⋅ 4 min read
Newsroom
GSK regulatory submission for momelotinib for the treatment of myelofibrosis accepted for review by Japanese regulator

For media and investors only- Regulatory submission included data from pivotal trials addressing key clinical manifestations of myelofibrosis, namely splenomegaly, constitutional sympto... Read More
GSK
2 years ago ⋅ English ⋅ 2 min read
Newsroom
GSK’s regulatory submission accepted for review by Japanese regulator for use of Nucala (mepolizumab) in adults with chronic rhinosinusitis with nasal polyps

For media and investors onlyGSK plc (LSE/NYSE: GSK) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has accepted for review a supplementary new drug appl... Read More